Skip to main content

A new approach for developing a less immunosuppressive tuberculosis vaccine

Objective

Infections due to Mycobacterium tuberculosis cause over 2 million deaths/year. A major problem in combating tuberculosis is the insufficient efficacy of the current vaccine, M. bovis BCG. This is due to the fact that BCG induces, apart from protective Th1 cytokines Il-12 and IFN, also the Th2 cytokine IL-4 and the immunosuppressive cytokine IL-10. Together, this response results in subversion of an adequate protective immunity.

Current data suggest that two mycobacterial glycolipids, lipoarabinomannan (LAM) and phenolic glycolipid (PGL) play an important role in this immunosuppression. For LAM it has been proposed that especially the terminal mannose residues, the mannose cap, are responsible for its immunosuppressive activity. We will use a new strategy to overcome these known problems of inefficacy by making less immunosuppressive BCG strains that lack PGL and/or (parts of) the mannose cap.

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

NEDERLANDS VACCIN INSTITUUT
Address
Antonie Van Leeuwenhoeklaan 11
Bilthoven
Netherlands

Participants (3)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Rue Michel-ange, 3
Paris
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR - IBMC
Portugal
Address
Rua Do Campo Alegre 823
Porto
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Netherlands
Address
De Boelelaan 1105
Amsterdam